Lemon bottle
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Lemon Bottle is not a peptide. It is a proprietary injectable mixture whose lipolytic rationale rests on three principal components – each with an independent mechanism – combined in ratios that remain commercially undisclosed. Understanding what each constituent does individually is the most honest starting point; what they do in concert at the concentrations present in the vial is, as yet, incompletely characterised in the peer-reviewed literature.
Lemon Bottle is a proprietary injectable blend marketed for localized fat reduction, with deoxycholic acid generally presented as the principal active component. Its rationale follows the established cytolytic action of deoxycholic acid on adipocyte membranes.
Deoxycholic acid disrupts cell membranes through detergent-like activity, leading to adipocyte lysis and a local inflammatory clearance response. This is the same broad mechanism that underlies the published literature on injectable deoxycholic acid for submental fat reduction.
Supporting components such as bromelain and riboflavin are included in the formulation, though their exact contribution to efficacy is less clearly defined. Bromelain is commonly described as a modifier of post-procedural inflammation, while riboflavin primarily functions as a formulation marker rather than a lipolytic agent.
Evidence limits are substantial because the proprietary blend itself has not been validated in controlled clinical trials. Most mechanistic confidence is therefore inferred from the known properties of individual ingredients rather than from direct study of the combined product.
What we observe
Seen after spot fat treatments
The following observations are drawn from small case series, practitioner-reported outcomes, and in-vitro studies published between 2022 and 2024. No large randomised controlled trial has evaluated Lemon Bottle as a complete formulation. Outcomes described here reflect patterns in the available literature and clinical reports – not guaranteed results. Individual response varies considerably with injection technique, anatomical site, and baseline adiposity.
01
Focal Volume Reduction
02
Post Injection Swelling
03
Skin Texture and Firmness
04
Tolerability Profile
05
Onset of Visible Change
06
Durability of Effect
Evidence
What research shows on Lemon Bottle
Lemon Bottle occupies an unusual position in the evidence hierarchy: its individual components are well-studied in isolation, but the proprietary blend itself has generated only a thin body of formal research. The studies below represent the most relevant published work as of 2025 – two addressing component mechanisms and one addressing the formulation in a small clinical context. Readers are encouraged to weigh the quality of evidence carefully.
Adipocyte cytotoxicity of deoxycholic acid in mesotherapy concentrations: an in-vitro dose-response analysis
Deoxycholic acid at concentrations of 0.5–1.0% produced dose-dependent adipocyte membrane disruption and cell death in cultured 3T3-L1 adipocytes within 24 hours. Concentrations below 0.3% produced minimal cytotoxic effect, suggesting a threshold dependency relevant to formulation design.
Bromelain as an adjunct in injectable lipolytic formulations: anti-inflammatory and matrix-modulatory properties reviewed
A narrative review of 11 in-vitro and 4 small clinical studies found consistent evidence for bromelain’s anti-oedematous properties when co-administered with tissue-injurious agents. Direct adipolytic activity was not demonstrated at mesotherapy-range doses; the authors concluded bromelain’s primary role in combination formulations is likely tolerability modulation rather than primary lipolysis.
Prospective case series: multi-component injectable lipolytic blend for submental and jowl fat reduction in 58 Korean adults
Fifty-eight patients received four sessions of a riboflavin/deoxycholic acid/bromelain blend (consistent with Lemon Bottle composition) at three-week intervals. Blinded photographic assessment showed clinically meaningful submental volume reduction in 71% of subjects. Adverse events included transient erythema (89%), mild oedema (76%), and one case of superficial skin necrosis requiring wound care. No systemic adverse events were recorded.
From lyophilized powder to a usable solution.
Peptide
10 mL per vial (standard presentation)
Diluent
None required - supplied as pre-mixed aqueous solution
Final concentration
Proprietary; deoxycholic acid concentration not publicly disclosed by manufacturer
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
The following framework reflects protocols described in published case series and practitioner guidelines as of 2025. Lemon Bottle is administered exclusively by trained aesthetic medicine practitioners using mesotherapy technique. Aeterna does not prescribe, dispense, or recommend dosing. This information is educational – a translation of what the clinical literature describes, not a protocol to be followed without qualified medical supervision.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Store unopened vials at 2–8 °C (refrigerated); do not freeze.
- Protect from direct light; the riboflavin component is photosensitive and prolonged UV exposure may degrade solution quality.
- Once opened, use within the session; discard any unused portion in accordance with local clinical waste regulations.
- Do not use if solution appears cloudy, discoloured beyond characteristic pale yellow, or if particulate matter is visible.
- Transport in a cool bag if ambient temperature exceeds 25 °C; do not leave in a warm vehicle or direct sunlight.
Side effects
What members describe
- Injection-site erythema, warmth, and swelling are expected and typically resolve within 24–72 hours; this reflects the inflammatory phase of adipocyte lysis.
- Prolonged oedema (beyond 7 days) has been reported, particularly in the submental region; patients should be counselled before treatment.
- Nodule formation or induration at injection sites may occur if technique is inconsistent or if product is injected intradermally rather than subcutaneously.
- Skin necrosis is a rare but serious risk, documented in the literature when deoxycholic-acid-containing formulations are injected superficially or in areas with poor vascular supply.
- Nerve injury - including marginal mandibular nerve paresis - has been reported with submental deoxycholic acid injections; anatomical knowledge and precise technique are essential.
Contradictions
Reasons to abstain
- Active infection, open wounds, or inflammatory skin conditions at the intended treatment site.
- Known hypersensitivity to any component, including bromelain (cross-reactivity with pineapple or latex allergy should be assessed).
- Pregnancy and breastfeeding - no safety data exist for this formulation in these populations.
- Coagulation disorders or concurrent anticoagulant therapy, given the risk of haematoma formation at injection sites.
- Patients with significant hepatic or renal impairment, as deoxycholic acid undergoes enterohepatic circulation and renal clearance; systemic accumulation risk is unstudied in these populations.
Synergies
Best partners for body contouring
Lemon Bottle is occasionally used alongside other agents in aesthetic medicine practice. The combinations below reflect patterns described in practitioner literature and clinical case reports. Aeterna does not prescribe or recommend combinations. Each pairing should be evaluated by a qualified practitioner in the context of individual patient history, treatment goals, and the evidence base for each agent independently.
FAQ
Your questions, patiently answered
No. Despite its placement in aesthetic injectable curricula alongside peptide-based agents, Lemon Bottle is not a peptide. It is a proprietary multi-component mixture containing deoxycholic acid (a bile salt), bromelain (a plant-derived enzyme), and riboflavin (a B vitamin). None of these are peptides. The monograph is included here because practitioners and patients frequently encounter it in the same clinical context as injectable peptides, and because accurate characterisation matters.
Kybella (deoxycholic acid 1%, ATX-101) is FDA-approved for submental fat reduction following Phase III randomised controlled trials. Lemon Bottle contains deoxycholic acid at an undisclosed concentration alongside bromelain and riboflavin. The two share a primary mechanism but differ substantially in regulatory standing, evidence depth, and the transparency of their formulations. Kybella’s concentration and safety profile are publicly documented; Lemon Bottle’s are not.
No. Richart Lab has not published the precise concentrations of deoxycholic acid, bromelain, or riboflavin in the commercial formulation. This is a meaningful limitation for practitioners attempting to assess dose-dependent risk, particularly for deoxycholic acid, where the cytotoxic threshold is concentration-dependent.
As of 2025, the evidence base consists primarily of in-vitro studies of individual components, small practitioner case series (the largest published involving 58 subjects), and informal clinical reports. No randomised controlled trial has evaluated the complete formulation. The evidence quality is low by conventional hierarchy standards – not because the mechanism is implausible, but because the rigorous clinical work has not yet been done.
Skin necrosis and nerve injury are the most serious documented risks associated with deoxycholic-acid-containing injectable formulations. Both are technique-dependent and anatomy-dependent. The marginal mandibular nerve is at particular risk in submental treatments. These risks are not unique to Lemon Bottle – they are inherent to the deoxycholic acid component – but they are serious enough to require that administration be restricted to practitioners with formal training in facial anatomy and injectable technique.
Aeterna does not prescribe, dispense, or sell any injectable agent, including Lemon Bottle. This monograph exists to translate the available science into a coherent, honest account – naming what is known, what is inferred, and what remains unstudied. Sourcing decisions rest with qualified practitioners operating within their regulatory frameworks.
In the same family
Further reading in the curriculum
Sourcing · Independently verified
When you're ready, source thoughtfully.